Document is current

Article History

First Online: 16 June 2026

Competing interests

: D.J.B. declares advisory or consulting roles at AIMED BIO, Astellas, AVEO Oncology, Bayer, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Janssen, Janux, Merck KGaA and Seagen; speakers’ bureau roles at Merck Sharpe Dohme; and travel and accommodations from DAVA Oncology, Merck KGaA, Merck Sharpe Dohme and Seagen. A.R.K. declares stock and other ownership interests at ECOM Medical; consulting or advisory roles at Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau roles at Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding from Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and expenses from Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. The other authors declare no competing interests.